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Abstract
Background: Long-term survival for combined aortic and mitral valve replacement appears to be
determined by the mitral valve prosthesis from our previous studies. This 21-year retrospective
study assess long-term outcome and durability of aortic valve replacement (AVR) with either
concomitant mitral valve replacement (MVR) or mitral valve repair (MVrep). We consider only a
single mechanical prosthesis.
Methods: Three hundred and sixteen patients underwent double valve replacement (DVR) (n =
273) or AVR+MVrep (n = 43), in the period 1977 to 1997. Follow up of 100% was achieved via
telephone questionnaire and review of patients' medical records. Actuarial analysis of long-term
survival was determined by Kaplan-Meier method. The Cox regression model was used to evaluate
potential predictors of mortality.
Results:  There were seventeen cases (5.4%) of early mortality and ninety-six cases of late
mortality. Fifteen-year survival was similar in both groups at 44% and 57% for DVR and
AVR+MVrep respectively. There were no significant differences in valve related deaths,
anticoagulation related complications, or prosthetic valve endocarditis between the groups. There
were 6 cases of periprosthetic leak in the DVR group. Sex, pre-operative mitral and aortic valve
pathology or previous cardiac surgery did not significantly affect outcome.
Conclusion: The mitral valve appears to be the determinant of survival following double valve
surgery and survival is not significantly influenced by mitral valve repair.
Background
Replacement of the aortic valve at the time of double valve
surgery is not contentious. However, the relative merits of
either mitral valve repair or mitral valve replacement in
these patients remains to be elucidated. In our previous
study over 13 years with the St. Jude Medical (SJM)
mechanical prosthesis valve, we observed that long-term
survival for combined aortic and mitral valve replacement
was similar to that for mitral valve replacement alone [1].
Therefore, we decided to include in present study all
patients with a SJM aortic valve replacement (AVR), and
concomitant mitral valve repair (MVrep) or mitral valve
replacement (MVR) in a 21-year period to determine
long-term survival for combined procedures. This study
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considered only patients in whom the SJM prosthesis was
used for valve replacement.
Methods
Three hundred and sixteen patients (227 female; 89 male)
had AVR with either mitral valve replacement (DVR n =
273) or mitral valve repair (AVR+MVrep n = 43), between
January 1977 and December 1997. All prosthetic valves
were St. Jude Medical (SJM) mechanical prosthesis (St.
Jude Medical, St. Paul. Mn.)
In the MVrep group, 28 patients had open mitral com-
misurotomy and 15 patients annuloplasty representing
mitral stenosis and rheumatic fever as the major cause of
mitral valve disease in this group.
The New York Heart Association (NYHA) functional clas-
sification III or IV was similar in each group (DVR 55.7%;
AVR +MVrep 67.4%) (p = NS). The median age of patients
undergoing DVR was 60.1 + 9.4 and 57.9 + 8.6 in the AVR
+ MVrep group (p = NS).
Patient clinical characteristics and pre-operative valve
pathophysiology are shown in Table 1.
Rheumatic or degenerative pathology was determined
according to pre-operative diagnosis, intra-operative and
pathological assessment. All patients with symptomatic
mitral valve disease following an episode of confirmed
endocarditis prior to surgery were considered as mitral
valve disease secondary to endocarditis.
Concomitant procedures included coronary artery bypass
grafting (CABG) in 37 patients, of which 5(11.6%)
patients underwent mitral valve repair and 32 (11.7%)
patients underwent mitral valve replacement (p = NS).
Thirty-seven patients had tricuspid valve repair, including
2(4.7%) with MVrep and 35(12.8%)patients with DVR (p
= NS).
Previous cardiac surgery was performed in 144(52.7%)
patients in the DVR group and 9(20.9%) patients in the
AVR+MVrep group (p = 0.0001), which suggests a greater
likelihood to replace the valve at the time of redo opera-
tion (Table 2).
Surgical procedure
A total of 589 prosthetic valves were implanted, 316 of
these were aortic and 273 mitral. The median implanted
valve size in the aortic position was 23 mm(19–29) and
in the mitral position 31 mm(25–33).
The operative technique varied depending on the surgeon
performing the procedure, but all surgeons used moderate
hypothermia (28°C to 32°C) along with cold crystalloid
or blood cardioplegia. Mitral valve repair or replacement
was the decision of the individual surgeon. Mitral valve
repair was classified as all procedures performed in keep-
ing with the techniques as originally described by carpen-
tier [2].
All patients were anticoagulated with warfarin. The goal
for the therapeutic range of international normalised ratio
(INR) was 2.0 to 3.0 and more recently (1992 onwards),
2.0 to 2.5 for AVR +MVrep and 2.5 to 3.0 for DVR. The
changes in INR resulted from data previously published
from our unit showing a decrease in haemorrhagic events
with no resultant changes in thromboembolic complica-
tions for isolated mechanical prosthesis in the aortic posi-
tion [1]. Until a therapeutic international normalized
Table 2: Reoperation patient characteristics
DVR AVR+Mvrep
n 144(52.7%) 9(20.9%)
Age (median ± SD) 59.2 ± 9.3 56.0 ± 1.6
Previous operation
Aortic valve 12(4.4%) 2(4.7%)
Mitral valve 68(24.9%) 6(14%)
Aortic and Mitral valves 57(20.9%) 1(2.3%)
Other than valve 4(1.5%) 0
Unknown 3(1.1%) 0
Table 1: Patient Characteristics
DVR AVR+Mvrep p
n 273 43
Age (median ± SD) 60.1 ± 9.4 57.9 ± 8.6 0.13
Female 197(72.2%) 30(70%) 0.72
NYHA III+IV 152(55.7%) 29(67.4%) 0.18
Valvular Pathology
Rheumatic 211(77.3%) 31(72.1%) 0.44
Degenerative 56(20.5%) 8(18.6%) >0.999
Ischaemic 4(1.5%) 1(2.3%) 0.52
Endocarditis 2(0.7%) 3(7.0%) 0.02
Mitral valve lesion
Stenosis 94(34.4%) 21(48.8%) 0.088
Regurgitation 73(26.7%) 9(20.9%) 0.46
Mixed 99(36.3%) 7(16.3%) 0.009
Unknown 7(2.6%) 6(14%)
Aortic valve lesion
Stenosis 66(24.2%) 16(37.2%) 0.09
Regurgitation 88(32.2%) 9(20.9%) 0.16
Mixed 113(41.4%) 16(37.2%) 0.74
Unknown 6(2.2%) 2(4.7%)
Patient Years 1993 381
NYHA = New York Heart AssociationJournal of Cardiothoracic Surgery 2007, 2:24 http://www.cardiothoracicsurgery.org/content/2/1/24
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ratio was achieved, patients were maintained in hospital
on either subcutaneous heparin or enoxaparin.
Data collection and follow up
Follow-up for surviving patients was carried out by tele-
phone interview with the patient, their family physician,
or a close relative during a closing interval of 220 days and
ranged from 3 months to 21 years (9.03 + 4.82 years).
During the follow up period 96 patients died. Overall,
50% of surviving patients were followed to 8.02 years,
36.7% to 10 years and 9.6% to 15 years.
Data for deceased patients were obtained from hospital
and family physicians' records as well as from death certif-
icates obtained from the Statistics and Research Agency of
Northern Ireland. We adhered to the guidelines of the
Society of Thoracic Surgeons [3] for reporting morbidity
and mortality after cardiac valvular operations. Follow up
of 100% was achieved with a total of 2374 patient years.
Statistical analysis
Continuous variables were expressed as median + stand-
ard deviation. For univariate comparisons the Χ2 test and
Fisher's exact probability test were used. A p value of less
than 0.05 was considered to be significant. The Kaplan-
Meier method was used for actuarial analysis, applying
either Breslow's or log-rank significance tests. All opera-
tive deaths were included in actuarial analysis. The Stats-
direct software package (Statsdirect.com) was used with a
compatible desktop computer.
Results
In hospital mortality
Seventeen patients (5.4%) died either in hospital or in the
first 30 days following operation (range 0 to 40 days). Of
these patients 16 had undergone DVR and 1 AVR+MVrep
(p = NS). The major causes of hospital death were post-
operative low cardiac output (8) or multiple organ failure
(2). One death occurred due to fracture of the aortic pros-
thetic valve. A further death occurred due to rupture of the
left ventricle along the posterior atrio-ventricular junction
in a patient undergoing DVR following two previous
mitral valve procedures.
Late mortality
Ninety-six patients died during the follow-up period. The
causes of death are listed in table 3.
Valve related deaths
We documented a total of thirty-eight deaths as valve-
related. Thirty-three occurred in the DVR group: myocar-
dial infarct (9), prosthetic valve endocarditis (8), intracra-
nial haemorrhage (7), thromboembolic CVA (5),
mesenteric infarct (2), mitral valve thrombosis (1), and
periprosthetic leak (1). There were five valve related
deaths within the AVR+MVrep group: myocardial infarct
(1), prosthetic valve endocarditis (2), thromboembolic
CVA (1), and sudden death (1). The patient who died of
sudden death died at home nine years following surgery
and no post-mortem was performed. The death was pre-
sumed to be valve-related, for the purposes of analysis (p
= NS).
Anticoagulation related complications
Thromboembolic complications were observed in 14 of
273 (5.1%) patients in the DVR group these included:
thromboembolic CVA (10), mesenteric infarction (2),
and valve thrombosis (2). Of these 14 patients there were
8 deaths (as detailed above). One patient with mitral
valve thrombosis had an international normalized ratio
of 1.4 times normal on admission and was treated suc-
cessfully with anticoagulation. There were two episodes of
thromboembolic CVA (4.7%) in the AVR+MVrep group
with one mortality (p = NS).
Haemorrhagic complications were observed in 12 (4.4%)
patients in the DVR group: intracranial haemorrhage (7),
gastrointestinal bleed (4), and nose bleed (1). All of the
patients with intracranial haemorrhage died, and the
other patients all required admission to hospital and
blood transfusion. Haemorrhagic complications were
observed in 3 of 43 (7.0%) patients in the AVR+Mvrep
group: gastrointestinal bleed (1), per vaginal bleed (1),
nose bleed(1). There were no mortalities but all required
blood transfusion (p = NS)
Prosthetic valve endocarditis
Twelve patients (12/316) patients were identified as hav-
ing prosthetic valve endocarditis (PVE). Three patients (3/
43;7.0%) in the AVR+MVrep group had PVE, two died and
one survives. He remains well after conservative manage-
ment. In the DVR group there were 9 patients (9/
273;3.3%) who developed PVE (p = NS). Eight patients
Table 3: Late causes of death
Cause of death DVR(n =) AVR+MVrep
(n =)
p
Valve Related Mortality 33 5 NS
Failed Heart Transplant 0 1
Total Cardiac Deaths 54 9 NS
Total non-Cardiac Deaths 28 5 NS
Pneumonia 10 2
Metastatic Disease 11 2
Renal Failure 2 0
Pulmonary Embolism 2 0
Septicaemia 2 0
Alcoholic Cirrhosis 1 0
Total Deaths 82 14 NSJournal of Cardiothoracic Surgery 2007, 2:24 http://www.cardiothoracicsurgery.org/content/2/1/24
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died and one survives following conservative manage-
ment.
Structural dysfunction
One patient died on the day of surgery in the DVR group
and post mortem showed a fracture of one of the aortic
valve leaflets.
Non-structural dysfunction
One patient in the DVR group required re-operation and
further mitral valve replacement six years later for mitral
valve leaflet entrapment due to pannus formation.
Periprosthetic leak
Six patients in the DVR group required re-operation for
periprosthetic leak, whilst no patients in the AVR+MVrep
group developed a leak (P = NS). Of those patients in the
DVR group requiring re-operation, one was for aortic
valve periprosthetic leak and five for mitral valve peripros-
thetic leak.
Actuarial analysis
At follow up, 203 patients were alive to give a total of
2374 patient years for this study. Actuarial survival,
regardless of cause of death, for DVR at 5, 10, 15 years was
79%(CI 74–84), 62%(CI 55–68), 44(CI 34–53) respec-
tively, and 86%(CI75–96), 76%(CI62–90), 57%(CI36–
79) respectively for the AVR+MVrep group (p = NS).
Actuarial survival for the patients(n = 163) undergoing
either DVR or AVR+MVrep, as a first time cardiac proce-
dure, at 5, 10, 15 years was 81%(CI 74–88), 58%(CI 47–
69), 39%(CI 21–56), and 82%(CI69–95), 77%(CI62–
93), 58%(CI32–84) for the DVR and AVR+MVrep groups
respectively (p = NS).
Cox regression analysis was performed using all patients
with the variables; procedure performed, sex, mitral valve
pathology, aortic valve pathology and redo procedure.
Using a forward selection process, only the variable age
was significant (p < 0.001), with all the other variables
exceeding p = 0.05. However, these results should be
treated with caution given the relatively small sample size.
Age significantly affects survival with a hazard ratio of
1.93 (CI 1.47–2.45) per decade.
Discussion
Our experience in this 21-year study shows that both DVR
and AVR+MVrep lead to excellent long-term survival and
low morbidity as comparable to other studies [4-7].
The higher early mortality rate appears less favourable
than other studies [8-12]. This may be related to the high
proportion of patients in NYHA III-IV. Moreover, there
was a high incidence of patients undergoing redo opera-
tions (153/316; 48.4%). Although redo operation follow-
ing previous mitral valve repair is associated with low
mortality [13] a number of these patients had previous
valve replacement which is associated with a higher oper-
ative mortality. Patients undergoing concomitant coro-
nary artery bypass were also included and again this is
associated with higher mortality [13]. These data were
also analysed for the twenty-one years as a whole. Interest-
ingly, the data for the United Kingdom heart valve registry
[14] over the period 1987–1997 estimates early mortality
at 9.3% for double valve procedures inclusive of re-opera-
tions.
Much of the data recently published comparing DVR to
AVR+MVrep considers a heterogeneous population of
patients undergoing replacement with various mechanical
and bioprosthetic valves [4-6]. A major strength of this
study, is that it is confined to a single prosthetic valve and
hence removes the confounding influences of the differ-
ent mechanical valves and the earlier structural deteriora-
tion associated with bioprosthetic valves.
Gillinov et al [5] had a population of 813 patients under-
going combined aortic valve replacement with mitral
valve procedure. They included all patients undergoing
surgery irrespective of the valvular prosthesis used during
the 23 year period. In total they identified 301 patients
receiving a mechanical aortic prosthesis with associated
mitral procedure, compared to 316 in the current study.
Long term survival was comparable in both studies. How-
ever, the high incidence of bioprosthetic valve insertion in
their study population resulted in a higher re-operation
rate, as would be expected. Hamamoto et al [4] also stud-
ied a similar population, again regardless of the type of
prosthesis used. Additionally, they excluded patients
undergoing concomitant coronary artery bypass grafting
or other procedure. In comparison, only 135 patients
within the DVR (135/299) group received a mechanical
prosthesis and 31 patients in the AVR+MVrep group
received a mechanical prosthesis in the aortic position.
Remadi et al [6] studied 254 consecutive patients under-
going mechanical valve replacement simultaneously of
the aortic and mitral valves. Although all mitral valve
replacements were with a SJM prosthesis, only 127
patients received such a valve in the aortic position. They
exhibited a higher early mortality rate of 7.08% but noted
that following this, long-term outcome for DVR was sim-
ilar to that for isolated MVR. They too, discovered a high
incidence of periprosthetic leak for patients undergoing
mechanical DVR.Journal of Cardiothoracic Surgery 2007, 2:24 http://www.cardiothoracicsurgery.org/content/2/1/24
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Freedom from thromboembolic complications at 10 years
was similar for each group (DVR 29% (CI 15–43);
AVR+MVrep 41% (CI 4–79)). There was also no signifi-
cant difference in the freedom from haemorrhagic com-
plications resulting from anticoagulation therapy.
This study population exhibited a high number of redo
operations following previous cardiac surgery (DVR n =
144; AVR+MVrep = 9). In our experience all patients
requiring a redo operation had a previous valve other than
a SJM, usually a bioprosthesis, inserted at the time of the
first cardiac procedure. Survival analysis of patients under-
going first time cardiac surgery of either DVR or
AVR+MVrep was similar at 15 years and was independent
of concomitant tricuspid valve repair or coronary artery
bypass grafting.
There was one re-operation within the AVR+MVrep group
with the patient undergoing a further AVR+MVrep. In this
case the aortic valve was initially replaced with a biopros-
thetic valve. In contrast, there were 6 re-operations for
periprosthetic leak within the DVR group. There were no
further valve procedures within the DVR group.
In their study Hamamoto et al [4] found that 49% of
patients (39/80) required re-operation following
AVR+MVrep. However 34 (87.2%) of these patients
required re-operation for deterioration of a bioprosthetic
valve in the aortic position or pannus associated with a
mechanical AVR.
There was a higher incidence of rheumatic fever in the
DVR group suggesting that surgeons were more likely to
perform a mitral valve replacement for a stenotic rheu-
matic mitral valve.
The operative mortality rates were 5.9% and 2.3% respec-
tively for DVR and AVR+Mvrep, suggesting a clinical dif-
ference.
As is common to retrospective reviews this study has sev-
eral limitations. Obviously patients were not randomised
to the two treatment modalities. The decision to perform
either DVR or AVR+MVrep was dependent on the operat-
ing surgeon and thus indications naturally varied accord-
ing to surgical experience. The absolute numbers of
patients were relatively small, but these are at least com-
parable to recently reported series [4-6].
Conclusion
Our previous data shows that survival following DVR is
similar to that for isolated MVR - see Fig 1. This current
study suggests that patients undergoing combined aortic
and mitral valve procedures may benefit from mitral valve
repair but unfortunately the available data but did not
reach a statistically significant difference in outcome for
survival. The authors accept that as a result of the disparity
in patient numbers between the two study groups, there is
a suggested clinical difference. Both mitral valve repair
and replacement are good options for the rheumatic valve
patient and the choice should be determined by surgical
judgement and experience. Whether repairing or replacing
a rheumatic mitral valve at the time of aortic valve replace-
ment makes no significant difference to long-term out-
come. These results must be interpreted with caution,
however, in the modern era with more myxomatous
mitral valve pathology amenable to repair. This study also
demonstrates that the use of a mechanical prosthesis in
this subgroup of patients results in good long-term sur-
vival without the need for reoperation associated with a
bioprosthetic valve.
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Kaplan-Meier survival curve for all patients undergoing DVR  or AVR+MVrep (log rank p = 0.18) Figure 1
Kaplan-Meier survival curve for all patients undergoing DVR 
or AVR+MVrep (log rank p = 0.18).
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